Efficacy and safety of AZD3199, an inhaled ultra long-acting β2 -agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD: preliminary observations Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002